A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

ClinicalTrials.gov ID: NCT03834584

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03834584. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-636, an oral Dihydroorotate Dehydrogenase (DHODH) inhibitor, in subjects with advanced lymphoma.

Study identification

NCT ID: NCT03834584
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Enrollment: 11 participants

Conditions and interventions

Conditions

Lymphoma

Interventions

AG-636 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 24, 2019 (Actual)
Primary completion: Jun 17, 2020 (Actual)
Completion: Jun 17, 2020 (Actual)
Last update posted: Aug 25, 2020

2019 – 2020

United States locations

U.S. sites: 6
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Yale Cancer Center	New Haven	Connecticut	06519	—
Moffitt Cancer Center	Tampa	Florida	33612	—
University of Nebraska Medical Center	Omaha	Nebraska	68198	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Weill Cornell Medical Center	New York	New York	10065	—
Seattle Cancer Care Alliance	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03834584, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 25, 2020 · Synced Nov 15, 2026